IDO1 and pulmonary arterial hypertension: Moreover, the predominant IDO-TM, kynurenine, has been more thoroughly investigated and, aside from being significantly higher in PAH patients (293–295), it correlated with mPAP and PVR (293) and could predict negative patient outcomes (294).